Each year since 2012 has seen record levels of mergers and acquisitions, with the peak of activity in 2015 (when deal values totalled $77bn) including the acquisition by Teva Pharmaceutical Industries Ltd. of Actavis generics (Allergan PLC), Pfizer Inc. buying Hospira Inc. and Endo International PLC acquiring Par Pharmaceutical. Either side of that peak, Mylan NV acquired Abbott Laboratories Inc.'s US generics business and Meda AB. Despite this, according to figures from McKinsey & Company, the aggregate market share of the top five generic medicines companies in markets such as France, Germany, and the US has fallen between 2012 and 2016 (Table 1).
Speaking at the CEO and Analyst Panel of the annual Medicines for Europe/IGBA meeting in Lisbon on 16 June, McKinsey Partner Simon Goeller, a specialist in the generics markets, said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?